TrialJournal of clinical pharmacology2026

Population Pharmacokinetics and Exposure-Response Analyses of Vepdegestrant, a First-in-Class PROteolysis-TArgeting Chimera Estrogen Receptor Degrader.

Derek Z Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.